Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC

Sign up for our daily newsletter

FDA flags new concerns on Hospira’s Rocky Mount plant

March 5, 2013 9:04 am by | 0 Comments

(Reuters) - Hospira Inc said U.S. health regulators issued a letter raising fresh concerns about one of the injectable-drugs maker's largest manufacturing plants in Rocky Mount, North Carolina, sending the company's shares down 4 percent.

Hospira's Rocky Mount facility has been under the FDA scanner since April 2010, when the regulator issued a warning letter stating manufacturing practices at the plant violated its defined standard practices.

The company said on Tuesday that the FDA inspected its Rocky Mount facility for three weeks and issued a letter outlining 20 concerns, three of which the agency had expressed earlier.

A number of these concerns were based on issues that are currently being resolved or have been identified by the company previously and would be addressed, Hospira said in a regulatory filing.


Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.